nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclizine—SULT1E1—Estrogen metabolism—CYP3A4—bone cancer	0.127	0.182	CbGpPWpGaD
Cyclizine—SULT1E1—Tamoxifen metabolism—CYP3A4—bone cancer	0.112	0.161	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—CYP4V2—bone cancer	0.104	0.149	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GSTP1—bone cancer	0.0304	0.0438	CbGpPWpGaD
Cyclizine—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.026	0.0374	CbGpPWpGaD
Cyclizine—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.0248	0.0358	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—CYP3A4—bone cancer	0.0208	0.03	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—CYP3A4—bone cancer	0.0205	0.0296	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—GSTP1—bone cancer	0.0178	0.0256	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—GSTP1—bone cancer	0.0175	0.0253	CbGpPWpGaD
Cyclizine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.014	0.0202	CbGpPWpGaD
Cyclizine—Reboxetine—CYP3A4—bone cancer	0.0139	0.17	CrCbGaD
Cyclizine—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.0125	0.0181	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—NDUFA12—bone cancer	0.0125	0.018	CbGpPWpGaD
Cyclizine—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.0121	0.0174	CbGpPWpGaD
Cyclizine—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.0112	0.0161	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—NT5C3A—bone cancer	0.0103	0.0149	CbGpPWpGaD
Cyclizine—Bifonazole—CYP3A4—bone cancer	0.00993	0.121	CrCbGaD
Cyclizine—Phenprocoumon—CYP3A4—bone cancer	0.00898	0.11	CrCbGaD
Cyclizine—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00861	0.0124	CbGpPWpGaD
Cyclizine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00821	0.0118	CbGpPWpGaD
Cyclizine—Pain—Carboplatin—bone cancer	0.00696	0.0311	CcSEcCtD
Cyclizine—Modafinil—CYP3A4—bone cancer	0.00652	0.0796	CrCbGaD
Cyclizine—Fentanyl—CYP3A4—bone cancer	0.00638	0.0779	CrCbGaD
Cyclizine—HRH1—G alpha (q) signalling events—GRM1—bone cancer	0.0061	0.00878	CbGpPWpGaD
Cyclizine—Prochlorperazine—CYP3A4—bone cancer	0.00607	0.074	CrCbGaD
Cyclizine—Benzphetamine—CYP3A4—bone cancer	0.00566	0.069	CrCbGaD
Cyclizine—Atomoxetine—CYP3A4—bone cancer	0.00561	0.0685	CrCbGaD
Cyclizine—Mianserin—CYP3A4—bone cancer	0.00549	0.067	CrCbGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00545	0.00786	CbGpPWpGaD
Cyclizine—Phenoxybenzamine—CYP3A4—bone cancer	0.00541	0.066	CrCbGaD
Cyclizine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00521	0.0075	CbGpPWpGaD
Cyclizine—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00514	0.00741	CbGpPWpGaD
Cyclizine—Blister—Epirubicin—bone cancer	0.00477	0.0213	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—ENO2—bone cancer	0.00453	0.00652	CbGpPWpGaD
Cyclizine—Blister—Doxorubicin—bone cancer	0.00441	0.0197	CcSEcCtD
Cyclizine—Apnoea—Methotrexate—bone cancer	0.00433	0.0193	CcSEcCtD
Cyclizine—Orphenadrine—CYP3A4—bone cancer	0.00429	0.0523	CrCbGaD
Cyclizine—Speech disorder—Methotrexate—bone cancer	0.00427	0.0191	CcSEcCtD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00422	0.00608	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—DHFR—bone cancer	0.0042	0.00605	CbGpPWpGaD
Cyclizine—HRH1—G alpha (q) signalling events—GNA11—bone cancer	0.00393	0.00566	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GNA11—bone cancer	0.00392	0.00565	CbGpPWpGaD
Cyclizine—Jaundice cholestatic—Epirubicin—bone cancer	0.00391	0.0175	CcSEcCtD
Cyclizine—Clozapine—CYP3A4—bone cancer	0.00366	0.0447	CrCbGaD
Cyclizine—Dyskinesia—Epirubicin—bone cancer	0.00366	0.0163	CcSEcCtD
Cyclizine—Jaundice cholestatic—Doxorubicin—bone cancer	0.00362	0.0162	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—CYP3A4—bone cancer	0.00356	0.00513	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—GRM4—bone cancer	0.00355	0.00511	CbGpPWpGaD
Cyclizine—Depressed level of consciousness—Methotrexate—bone cancer	0.00355	0.0158	CcSEcCtD
Cyclizine—Hepatobiliary disease—Cisplatin—bone cancer	0.00354	0.0158	CcSEcCtD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.00351	0.00506	CbGpPWpGaD
Cyclizine—Injection site reaction—Epirubicin—bone cancer	0.00342	0.0153	CcSEcCtD
Cyclizine—Dyskinesia—Doxorubicin—bone cancer	0.00338	0.0151	CcSEcCtD
Cyclizine—Connective tissue disorder—Cisplatin—bone cancer	0.0033	0.0147	CcSEcCtD
Cyclizine—Injection site reaction—Doxorubicin—bone cancer	0.00316	0.0141	CcSEcCtD
Cyclizine—Eye disorder—Cisplatin—bone cancer	0.00314	0.014	CcSEcCtD
Cyclizine—Thrombophlebitis—Methotrexate—bone cancer	0.00308	0.0137	CcSEcCtD
Cyclizine—HRH1—GPCR ligand binding—GRM1—bone cancer	0.00308	0.00443	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GSTP1—bone cancer	0.00304	0.00438	CbGpPWpGaD
Cyclizine—Erythema—Cisplatin—bone cancer	0.00292	0.0131	CcSEcCtD
Cyclizine—Thrombophlebitis—Epirubicin—bone cancer	0.00288	0.0129	CcSEcCtD
Cyclizine—Hepatic function abnormal—Epirubicin—bone cancer	0.00285	0.0127	CcSEcCtD
Cyclizine—Muscle spasms—Cisplatin—bone cancer	0.00281	0.0126	CcSEcCtD
Cyclizine—Vision blurred—Cisplatin—bone cancer	0.00276	0.0123	CcSEcCtD
Cyclizine—Tremor—Cisplatin—bone cancer	0.00274	0.0122	CcSEcCtD
Cyclizine—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.00267	0.00385	CbGpPWpGaD
Cyclizine—Thrombophlebitis—Doxorubicin—bone cancer	0.00267	0.0119	CcSEcCtD
Cyclizine—Hepatic function abnormal—Doxorubicin—bone cancer	0.00264	0.0118	CcSEcCtD
Cyclizine—Dermatitis bullous—Epirubicin—bone cancer	0.00261	0.0117	CcSEcCtD
Cyclizine—Convulsion—Cisplatin—bone cancer	0.00253	0.0113	CcSEcCtD
Cyclizine—Dermatitis bullous—Doxorubicin—bone cancer	0.00241	0.0108	CcSEcCtD
Cyclizine—Anaphylactic shock—Cisplatin—bone cancer	0.00239	0.0107	CcSEcCtD
Cyclizine—Nervous system disorder—Cisplatin—bone cancer	0.00234	0.0105	CcSEcCtD
Cyclizine—Tachycardia—Cisplatin—bone cancer	0.00233	0.0104	CcSEcCtD
Cyclizine—Skin disorder—Cisplatin—bone cancer	0.00232	0.0104	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.00224	0.00323	CbGpPWpGaD
Cyclizine—Hypotension—Cisplatin—bone cancer	0.00223	0.00996	CcSEcCtD
Cyclizine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.00221	0.00319	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—SMO—bone cancer	0.00217	0.00312	CbGpPWpGaD
Cyclizine—Paraesthesia—Cisplatin—bone cancer	0.00214	0.00957	CcSEcCtD
Cyclizine—Drowsiness—Methotrexate—bone cancer	0.00205	0.00917	CcSEcCtD
Cyclizine—Pain—Cisplatin—bone cancer	0.00204	0.00912	CcSEcCtD
Cyclizine—HRH1—GPCR downstream signaling—GRM4—bone cancer	0.002	0.00289	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—RGS1—bone cancer	0.002	0.00289	CbGpPWpGaD
Cyclizine—Hepatobiliary disease—Methotrexate—bone cancer	0.00194	0.00867	CcSEcCtD
Cyclizine—Drowsiness—Epirubicin—bone cancer	0.00192	0.00858	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.00192	0.00276	CbGpPWpGaD
Cyclizine—Agranulocytosis—Methotrexate—bone cancer	0.00192	0.00856	CcSEcCtD
Cyclizine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.00189	0.00273	CbGpPWpGaD
Cyclizine—Hepatitis—Methotrexate—bone cancer	0.00184	0.00823	CcSEcCtD
Cyclizine—HRH1—Signaling by GPCR—GRM4—bone cancer	0.00182	0.00262	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—RGS1—bone cancer	0.00182	0.00262	CbGpPWpGaD
Cyclizine—Hepatobiliary disease—Epirubicin—bone cancer	0.00182	0.00812	CcSEcCtD
Cyclizine—Agranulocytosis—Epirubicin—bone cancer	0.00179	0.00801	CcSEcCtD
Cyclizine—Drowsiness—Doxorubicin—bone cancer	0.00178	0.00794	CcSEcCtD
Cyclizine—Hypersensitivity—Cisplatin—bone cancer	0.00176	0.00785	CcSEcCtD
Cyclizine—HRH1—GPCR downstream signaling—GRM1—bone cancer	0.00174	0.0025	CbGpPWpGaD
Cyclizine—Hepatitis—Epirubicin—bone cancer	0.00173	0.00771	CcSEcCtD
Cyclizine—Eye disorder—Methotrexate—bone cancer	0.00172	0.00769	CcSEcCtD
Cyclizine—Asthenia—Cisplatin—bone cancer	0.00171	0.00765	CcSEcCtD
Cyclizine—Connective tissue disorder—Epirubicin—bone cancer	0.0017	0.00757	CcSEcCtD
Cyclizine—Hepatobiliary disease—Doxorubicin—bone cancer	0.00168	0.00751	CcSEcCtD
Cyclizine—Agranulocytosis—Doxorubicin—bone cancer	0.00166	0.00741	CcSEcCtD
Cyclizine—Chills—Methotrexate—bone cancer	0.00165	0.00739	CcSEcCtD
Cyclizine—Mental disorder—Methotrexate—bone cancer	0.00162	0.00721	CcSEcCtD
Cyclizine—Eye disorder—Epirubicin—bone cancer	0.00161	0.0072	CcSEcCtD
Cyclizine—Erythema—Methotrexate—bone cancer	0.00161	0.00717	CcSEcCtD
Cyclizine—Hepatitis—Doxorubicin—bone cancer	0.0016	0.00713	CcSEcCtD
Cyclizine—HRH1—Signaling by GPCR—GRM1—bone cancer	0.00158	0.00227	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PTGS2—bone cancer	0.00158	0.00227	CbGpPWpGaD
Cyclizine—Connective tissue disorder—Doxorubicin—bone cancer	0.00157	0.00701	CcSEcCtD
Cyclizine—Chills—Epirubicin—bone cancer	0.00155	0.00691	CcSEcCtD
Cyclizine—Vision blurred—Methotrexate—bone cancer	0.00151	0.00675	CcSEcCtD
Cyclizine—Mental disorder—Epirubicin—bone cancer	0.00151	0.00675	CcSEcCtD
Cyclizine—Erythema—Epirubicin—bone cancer	0.0015	0.00671	CcSEcCtD
Cyclizine—Eye disorder—Doxorubicin—bone cancer	0.00149	0.00666	CcSEcCtD
Cyclizine—Tension—Epirubicin—bone cancer	0.00147	0.00658	CcSEcCtD
Cyclizine—Nervousness—Epirubicin—bone cancer	0.00146	0.00651	CcSEcCtD
Cyclizine—Muscle spasms—Epirubicin—bone cancer	0.00144	0.00645	CcSEcCtD
Cyclizine—Chills—Doxorubicin—bone cancer	0.00143	0.0064	CcSEcCtD
Cyclizine—Vision blurred—Epirubicin—bone cancer	0.00142	0.00632	CcSEcCtD
Cyclizine—Mental disorder—Doxorubicin—bone cancer	0.0014	0.00625	CcSEcCtD
Cyclizine—Convulsion—Methotrexate—bone cancer	0.00139	0.00621	CcSEcCtD
Cyclizine—Erythema—Doxorubicin—bone cancer	0.00139	0.00621	CcSEcCtD
Cyclizine—Agitation—Epirubicin—bone cancer	0.00138	0.00616	CcSEcCtD
Cyclizine—Tension—Doxorubicin—bone cancer	0.00136	0.00609	CcSEcCtD
Cyclizine—Nervousness—Doxorubicin—bone cancer	0.00135	0.00603	CcSEcCtD
Cyclizine—CYP2C9—Metabolism—NDUFA12—bone cancer	0.00134	0.00194	CbGpPWpGaD
Cyclizine—Muscle spasms—Doxorubicin—bone cancer	0.00134	0.00597	CcSEcCtD
Cyclizine—Anaphylactic shock—Methotrexate—bone cancer	0.00131	0.00585	CcSEcCtD
Cyclizine—Vision blurred—Doxorubicin—bone cancer	0.00131	0.00585	CcSEcCtD
Cyclizine—Convulsion—Epirubicin—bone cancer	0.0013	0.00581	CcSEcCtD
Cyclizine—Hypertension—Epirubicin—bone cancer	0.0013	0.00579	CcSEcCtD
Cyclizine—Nervous system disorder—Methotrexate—bone cancer	0.00128	0.00574	CcSEcCtD
Cyclizine—Agitation—Doxorubicin—bone cancer	0.00128	0.0057	CcSEcCtD
Cyclizine—Skin disorder—Methotrexate—bone cancer	0.00127	0.00568	CcSEcCtD
Cyclizine—Anaphylactic shock—Epirubicin—bone cancer	0.00123	0.00547	CcSEcCtD
Cyclizine—Hypotension—Methotrexate—bone cancer	0.00122	0.00547	CcSEcCtD
Cyclizine—Convulsion—Doxorubicin—bone cancer	0.0012	0.00538	CcSEcCtD
Cyclizine—Nervous system disorder—Epirubicin—bone cancer	0.0012	0.00537	CcSEcCtD
Cyclizine—Hypertension—Doxorubicin—bone cancer	0.0012	0.00536	CcSEcCtD
Cyclizine—Tachycardia—Epirubicin—bone cancer	0.0012	0.00534	CcSEcCtD
Cyclizine—Skin disorder—Epirubicin—bone cancer	0.00119	0.00532	CcSEcCtD
Cyclizine—Insomnia—Methotrexate—bone cancer	0.00118	0.00529	CcSEcCtD
Cyclizine—Paraesthesia—Methotrexate—bone cancer	0.00118	0.00525	CcSEcCtD
Cyclizine—Somnolence—Methotrexate—bone cancer	0.00116	0.0052	CcSEcCtD
Cyclizine—Hypotension—Epirubicin—bone cancer	0.00115	0.00512	CcSEcCtD
Cyclizine—Anaphylactic shock—Doxorubicin—bone cancer	0.00113	0.00507	CcSEcCtD
Cyclizine—Pain—Methotrexate—bone cancer	0.00112	0.005	CcSEcCtD
Cyclizine—HRH1—GPCR downstream signaling—GNA11—bone cancer	0.00112	0.00161	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NT5C3A—bone cancer	0.00111	0.00161	CbGpPWpGaD
Cyclizine—Nervous system disorder—Doxorubicin—bone cancer	0.00111	0.00497	CcSEcCtD
Cyclizine—HRH1—Signaling by GPCR—SMO—bone cancer	0.00111	0.0016	CbGpPWpGaD
Cyclizine—Insomnia—Epirubicin—bone cancer	0.00111	0.00495	CcSEcCtD
Cyclizine—Tachycardia—Doxorubicin—bone cancer	0.00111	0.00494	CcSEcCtD
Cyclizine—Skin disorder—Doxorubicin—bone cancer	0.0011	0.00492	CcSEcCtD
Cyclizine—Paraesthesia—Epirubicin—bone cancer	0.0011	0.00492	CcSEcCtD
Cyclizine—Somnolence—Epirubicin—bone cancer	0.00109	0.00487	CcSEcCtD
Cyclizine—HRH1—Signaling Pathways—RGS1—bone cancer	0.00108	0.00155	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GRM4—bone cancer	0.00108	0.00155	CbGpPWpGaD
Cyclizine—Hypotension—Doxorubicin—bone cancer	0.00106	0.00473	CcSEcCtD
Cyclizine—Constipation—Epirubicin—bone cancer	0.00105	0.00468	CcSEcCtD
Cyclizine—Pain—Epirubicin—bone cancer	0.00105	0.00468	CcSEcCtD
Cyclizine—Urticaria—Methotrexate—bone cancer	0.00104	0.00465	CcSEcCtD
Cyclizine—Insomnia—Doxorubicin—bone cancer	0.00103	0.00458	CcSEcCtD
Cyclizine—Paraesthesia—Doxorubicin—bone cancer	0.00102	0.00455	CcSEcCtD
Cyclizine—HRH1—Signaling by GPCR—GNA11—bone cancer	0.00102	0.00146	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—IL3—bone cancer	0.00102	0.00146	CbGpPWpGaD
Cyclizine—Somnolence—Doxorubicin—bone cancer	0.00101	0.0045	CcSEcCtD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.001	0.00144	CbGpPWpGaD
Cyclizine—Urticaria—Epirubicin—bone cancer	0.000974	0.00435	CcSEcCtD
Cyclizine—Constipation—Doxorubicin—bone cancer	0.00097	0.00433	CcSEcCtD
Cyclizine—Pain—Doxorubicin—bone cancer	0.00097	0.00433	CcSEcCtD
Cyclizine—Hypersensitivity—Methotrexate—bone cancer	0.000965	0.00431	CcSEcCtD
Cyclizine—Asthenia—Methotrexate—bone cancer	0.00094	0.0042	CcSEcCtD
Cyclizine—HRH1—Signaling Pathways—GRM1—bone cancer	0.000932	0.00134	CbGpPWpGaD
Cyclizine—Pruritus—Methotrexate—bone cancer	0.000927	0.00414	CcSEcCtD
Cyclizine—HRH1—Signaling by GPCR—IL3—bone cancer	0.000922	0.00133	CbGpPWpGaD
Cyclizine—Hypersensitivity—Epirubicin—bone cancer	0.000903	0.00403	CcSEcCtD
Cyclizine—Urticaria—Doxorubicin—bone cancer	0.000901	0.00402	CcSEcCtD
Cyclizine—Asthenia—Epirubicin—bone cancer	0.00088	0.00393	CcSEcCtD
Cyclizine—Pruritus—Epirubicin—bone cancer	0.000867	0.00387	CcSEcCtD
Cyclizine—Dizziness—Methotrexate—bone cancer	0.000866	0.00387	CcSEcCtD
Cyclizine—Hypersensitivity—Doxorubicin—bone cancer	0.000836	0.00373	CcSEcCtD
Cyclizine—Headache—Methotrexate—bone cancer	0.000821	0.00366	CcSEcCtD
Cyclizine—Asthenia—Doxorubicin—bone cancer	0.000814	0.00363	CcSEcCtD
Cyclizine—Dizziness—Epirubicin—bone cancer	0.000811	0.00362	CcSEcCtD
Cyclizine—Pruritus—Doxorubicin—bone cancer	0.000803	0.00358	CcSEcCtD
Cyclizine—Headache—Epirubicin—bone cancer	0.000768	0.00343	CcSEcCtD
Cyclizine—Dizziness—Doxorubicin—bone cancer	0.00075	0.00335	CcSEcCtD
Cyclizine—Headache—Doxorubicin—bone cancer	0.000711	0.00317	CcSEcCtD
Cyclizine—HRH1—Signaling Pathways—SMO—bone cancer	0.000657	0.000946	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GNA11—bone cancer	0.000601	0.000865	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ATF1—bone cancer	0.000558	0.000805	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IL3—bone cancer	0.000545	0.000785	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ENO2—bone cancer	0.000488	0.000703	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TGFBR2—bone cancer	0.000466	0.000671	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—DHFR—bone cancer	0.000453	0.000652	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IGF1R—bone cancer	0.000438	0.000631	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GNA11—bone cancer	0.000423	0.00061	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP3A4—bone cancer	0.000384	0.000553	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000382	0.00055	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTP1—bone cancer	0.000328	0.000473	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—KIT—bone cancer	0.000318	0.000458	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—BRAF—bone cancer	0.000299	0.00043	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—EGFR—bone cancer	0.00029	0.000417	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MDM2—bone cancer	0.00025	0.000361	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—JUN—bone cancer	0.000218	0.000313	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MMP9—bone cancer	0.000212	0.000305	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—EGFR—bone cancer	0.000171	0.000246	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PTGS2—bone cancer	0.00017	0.000245	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TP53—bone cancer	0.000144	0.000207	CbGpPWpGaD
